Table 3 Characteristics of studies about FeNO variation in lung cancer patients between pretreatment and posttreatment
From: Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis
Year | Author | Country | Age (Mean ± SD) | Sex (M/F) | Smoking status (Mean ± SD) | Histology | Stage | Treatment | Follow up period | FeNO (ppb) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Before therapy | After therapy | ||||||||||||
Mean ± SD | n | Mean ± SD | n | ||||||||||
2001 | Koizumi | Japan | 61a (38–84) | 24/5 | NA | SCC, ADC, LCC, SCLC | early + advanced | radio-therapy | NA | 77.0 ± 47.0 | 29 | 49.0 ± 33.0 | 29 |
2006 | Wewel | Germany | 64 (12)b | 27/12 | 40 (29)b | NSCLC, SCLC | early + advanced | chemo-therapy | 21–29 days | 22.1 ± 10.1 | 34 | 24.5 ± 10.8 | 34 |
2012 | Enache | France | 61 ± 11 | 48/17 | NA | SCC, ADC, LCC, SCLC | early + advanced | radio-therapy | 7.5 months | 14.3 ± 7.2 | 65 | 18.2 ± 12.5 | 65 |
2013 | Kallianos | Greece | 65 ± 17 | 26/16 | 51 ± 7 | SCC, ADC, LCC, SCLC | NA | chemo-therapy | NA | 9.8 ± 2.1 | 42 | 7.7 ± 1.6 | 42 |
2014 | Moré | USA | 68a (54–89) | 14/6 | NA | NSCLC | NA | radio-therapy | 6 months | 26.3 ± 19.6 | 17 | 31.8 ± 22.9 | 17 |
2019 | Szejniuk | Denmark | 66a (40–78) | 24/18 | NA | NSCLC | early + advanced | radio-therapy | 12 months | 13.5 ± 7.6 | 42 | 16.8 ± 9.8 | 42 |
2019 | Suzuki | Japan | 69a (65–74) | 74/21 | NA | NSCLC | advanced | immune-therapy | NA | 21.5 ± 14.7 | 85 | 25.2 ± 16.8 | 85 |